Last deal

$10M

Amount

Venture - Series Unknown

Stage

29.02.2024

Date

3

all rounds

$82.94M

Total amount

date founded

Financing round

General

About Company
ONL Therapeutics develops therapeutics for retinal diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2011

founders

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

ONL Therapeutics is pioneering a new approach to preserve sight by preventing the death of key retinal cells, which is a root cause of vision loss and blindness. Their lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from death and inflammatory signaling pathways. The company is developing ONL1204 for the treatment of retinal detachment, as well as other indications such as age-related macular degeneration and glaucoma. ONL Therapeutics aims to address the unmet medical need of protecting photoreceptor cells, which is the initial neural component of vision loss.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Disarm Therapeutics

Disarm Therapeutics

Disarm Therapeutics develops disease-modifying therapeutics for patients with axonal degeneration.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Cambridge, MA, USA

total rounds

2

total raised

$30M
Aldeyra Therapeutics

Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company that develops and commercializes next-generation medicines for immune-mediated diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Burlington, MA, USA

total rounds

5

total raised

$287.39M
OcuTerra Therapeutics

OcuTerra Therapeutics

OcuTerra Therapeutics is developing a novel eye drop to treat diabetic eye disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boston, MA, USA

total rounds

3

total raised

$35M
Opsis Therapeutics

Opsis Therapeutics

Opsis Therapeutics develops first-in-class treatments for retinal diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Madison, WI, USA

Financials

Funding Rounds
9
3

Number of Funding Rounds

$82.94M

Money Raised

Their latest funding was raised on 29.02.2024. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Bios Partners

Bios Partners

Bios Partners is a venture capital firm that invests in innovative early-stage and growth-stage biotech and medical device companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Fort Worth, TX, USA

count Of Investments

14
Visionary Venture Fund

Visionary Venture Fund

Visionary is a venture capital firm that invests in emerging ophthalmology companies in medical devices and pharmaceuticals.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Venture Capital, Medical Device, Health Care

Location

Aliso Viejo, CA, USA

count Of Investments

21

count Of Exists

2

Mayewell Capital

Mayewell Capital is a healthcare-focused investment firm specializing in pharmaceuticals and biotechnology.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Health Care, Biotechnology, Pharmaceuticals

Location

Pennsylvania Furnace, PA 16865, USA

count Of Investments

1

Alpine Visionary

Alpine Visionary Venture invests in companies at various stages of financing, from Series A to late-stage.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

count Of Investments

1
Bios Partners

Bios Partners

Bios Partners is a venture capital firm that invests in innovative early-stage and growth-stage biotech and medical device companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Fort Worth, TX, USA

count Of Investments

14
Co-Investors
Investors
18
5

Number of lead investors

18

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series B, Series C
No
Convertible Note, Seed, Series A, Series B, Series C
Kaitai Capital

Kaitai Capital

Kaitai Capital is a professional investment management organization.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Wealth Management

Location

Hangzhou, Zhejiang, China

count Of Investments

126

count Of Exists

2
Johnson & Johnson Innovation

Johnson & Johnson Innovation

Johnson & Johnson Innovation collaborates with innovators to incorporate science into healthcare solutions.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Medical Device

Location

New Brunswick, NJ, USA

count Of Investments

60

count Of Exists

6
Marian Nakada

Marian Nakada

Marian Nakada, PhD, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in Boston, MA. Previously, Dr. Nakada was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy. Dr. Nakada joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Dr. Nakada joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor's technologies were competitive with the industry. Dr. Nakada has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.

current job

Women in VC
Women in VC
Capital Community Angel Investors

Capital Community Angel Investors

Capital Community Angel Investors connects Michigan-based startups with early-stage capital.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

East Lansing, MI, USA

count Of Investments

16

count Of Exists

1

People

Founders
1
David Zacks
David Zacks

David Zacks

Co-Founder/CSO at ONL Therapeutics.

current job

ONL Therapeutics
ONL Therapeutics

organization founded

1

David Zacks

Employee Profiles
6
Sushanta Mallick

Sushanta Mallick

Chief Development Officer

David Esposito

David Esposito

President & Chief Executive Officer

Bob Forgey

Vice president operations

David Zacks

David Zacks

Co-Founder/CSO

David M. Kleinman

David M. Kleinman

CMO

Activity

Recent News
1